Analyst Coverage

The following organisations provide research coverage on Pharmaxis:

Bell Potter Securities Limited

Analyst: Tanushree Jain (tnjain@bellpotter.com.au)

Bell Potter initiated coverage on 8 December 2017.

For copies of current reports contact Bell Potter.

13 February 2021	1H21 – Result Summary
7 January 2021	FDA approval for Bronchitol revamps the business, improves outlook
7 September 2020	BI terminates agreement, discontinues development of partnered drug
19 August 2020	FDA clears IND for myelofibrosis study
13 August	FY20 Audited Results - No Material Change
5 August 2020	Key catalysts expected in Q4CY20
22 May 2020	COVID-19 impacting timing for key catalysts
13 February 2020	1H20 Audited Results - No Material Change
6 February 2020	Down but not out, with turnaround prospects strong in CY20
25 November 2019	Approaching key inflection points
16 August 2019	FY19 Audited Results - No material change
30 July 2019	Key catalysts coming up in FY20
24 June 2019	FDA Issues CRL on Bronchitol - approval now expected in early 2020
15 May 2019	Bronchitol gets positive recommendation from Adcom by a narrow majority
15 February 2019	Strong cash position and approaching key inflection points
30 April 2018	Interim data from Phase 1 LOXL-2 program strengthen partnering prospects
16 February 2018	1H18 Results - no material change from unaudited results released earlier
1 February 2018	Good clinical and partnering progress on LOXL-2 asset
11 January 2018	BI milestone strengthens balance sheet, LOXL-2 moves into the clinic
8 December 2017	Emerging as a key player in multi-billion dollar NASH market

Bioshares

Editors: David Blake and Mark Pachacz (info@bioshares.com.au)

Read Bioshares most recent reports:

19 April 2021	Karst Peak Continues Investment in Austalia Biotech
15 February 2021	Pharmaxis Makes First Commercial Bronchitol Shipment to USA
3 November 2020	Bronchitol FDA Approval a Turning Point for Pharmaxis
7 September 2020	Boehringer Ends Development of Pharmaxis Compound
10 August 2020	A Big Six Months Ahead for Pharmaxis
4 May 2020	Pharmaxis - Multiple Assets to Drive Value
24 February 2020	Pharmaxis Remains Confident of Securing LOXL2 Deal
24 December 2019	Top Six Stock Picks – 2020
19 December 2019	Boehringer Ingelheim Discontinues NASH Program; Continues in Diabetic Retinopathy
28 October 2019	PXS Completes Phase Ia Trial of PXS5505A
24 June 2019	Pharmaxis' Bronchitol Edges Closer to FDA Approval
13 May 2019	Pharmaxis Gains Positive Vote for Bronchitol in USA
29 April 2019	Pharmaxis Update
25 February 2019	Pharmaxis Tackles the Intractable
25 January 2019	Pharmaxis' LOXL2 Program Ready for a Deal
10 December 2018	Pharmaxis Investor Briefing Summary
12 October 2018	More Positive Phase I Data from LOXL2 Program
13 August 2018	Pharmaxis strengthens balance sheet ahead of LOXL2 licensing deal
20 July 2018	Interview with Dr Kathleen Metters
8 May 2018	Pharmaxis – a drug developer with a deal making record
5 February 2018	A busy year for Pharmaxis – multiple trial readouts ahead
8 September 2017	Pharmaxis – Boehringer selects diabetic retinopathy as second indication
4 September 2017	Pharmaxis' partner starts phase II NASH trial
24 March 2017	Three share price drivers for Pharmaxis
28 October 2016	Pharmaxis. All attention on NASH for Pharmaxis